natgillin/translations-raw huggingface dataset:
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, wherein: 
ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, solvat ili hidrat tog spoja, gdje:
is A compound according to claim 1, wherein the compound is selected from: 
Spoj u skladu sa patentnim zahtjevima 1-6, gdje spoj je odabran od
A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1 . 
Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljivi nosač i spoj iz bilo kojeg od patentnih zahtjeva 1-9.
The method according to claim 1, wherein the reference point includes the predetermined touch point or a coordinate origin identified using the predetermined touch point. 
Metoda u skladu sa zahtjevom 1, naznačena time što referentna točka uključuje određenu točku dodira ili izvor koordinata identificiran pomoću određene točke dodira.
The method according to claim 1, wherein the receiving the touch point information includes reading the geometric structure of the touch points corresponding to the touch point information based on a designed geometric structure condition for arranging a plurality of touch portions in a flat plate area of a frame portion included in the touch device, and identifying a specified touch point fixed and arranged in a specified position within the flat plate area. The method according to claim 1, 
Metoda u skladu sa zahtjevom 1, naznačena time što drugi korak uključuje očitavanje geometrijske strukture točaka dodira koje odgovaraju podacima točaka dodira na temelju uvjeta dizajnirane geometrijske strukture za raspoređivanje više dodirnih dijelova (300) u ravnom području ploče (205) dijela okvira (200) koji je uključen u dodirnom uređaju i identificiranje određene točke dodira koja je fiksirana i postavljena u određenom položaju unutar područja ravne ploče (205).
coordinate-transforming the predetermined touch point and other touch points into a coordinate system corresponding to the designed geometric relationship upon identifying the predetermined touch point. 
koordinatno-transformiranje određene točke dodira i drugih točaka dodira u koordinatni sustav koji odgovara dizajniranom geometrijskom odnosu nakon identificiranja određene točke dodira.
calculating a geometric relationship of the rotated touch points. 
izračunavanje geometrijskog odnosa koordinatno rotiranih točaka dodira.
wherein a compound of formula (9): is allowed to react with a compound of formula (9b): thereby providing copanlisib (10): said compound of formula (9): being prepared by the following step A8: 
pri čemu je spoj s formulom (9): ostavljen da reagira sa spojem s formulom (9b): čime se dobiva kopanlisib (10): navedeni spoj s formulom (9): pripravlja se u sljedećem koraku A8:
wherein a compound of formula (8): is allowed to react with a compound of formula (8a): in a solvent, thereby providing a compound of formula (9); 
pri čemu je spoj s formulom (8): ostavljen da reagira sa spojem s formulom (8a): u otapalu, čime se dobiva spoj formule (9);
wherein a compound of formula (7): is allowed to react with a reducing agent, thereby providing a compound of formula (8); 
pri čemu je spoj s formulom (7): ostavljen da reagira s redukcijskim sredstvom, čime se dobiva spoj formule (8);
wherein a compound of formula (6): is allowed to react with an annelating agent, thereby providing a compound of formula (7); 
pri čemu je spoj s formulom (6): ostavljen da reagira sa sredstvom za aneliranje, čime se dobiva spoj formule (7);
wherein a compound of formula (5): is allowed to react with a reducing agent, thereby providing a compound of formula (6). 
pri čemu je spoj s formulom (5): ostavljen da reagira sa redukcijskim sredstvom, čime se dobiva spoj formule (6).
The method according to any one of claims 1 to 8, wherein said step A7 is in the presence of a catalyst, such as a metallic catalyst such as palladium on charcoal for example, particularly 5% palladium on charcoal which is water-wetted, optionally dissolved in a solvent or in suspension in a solvent, such as N,N-dimethylformamide for example. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je navedeni korak A7 u prisutnosti katalizatora, kao što je metalni katalizator kao što je paladij na ugljenu na primjer, naročito 5% paladij na ugljenu koji je navlažen vodom, po izboru otopljen u otapalu ili u suspenziji u otapalu, kao što je na primjer N,N-dimetilformamid.
The method according to any one of claims 1 to 9, wherein step A7 is in presence of an acid, such as trifluoroacetic acid for example. 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time što je korak A7 u prisutnosti kiseline, kao što je na primjer trifluorooctena kiselina.
The method according to any one of claims 1 to 14, wherein said step A5 is in the presence of a catalyst, such as a bimetallic catalyst such as platinum/iron on charcoal for example, particularly 1% Pt/0.2% Fe/C, which is water-wetted, optionally dissolved in a solvent or in suspension in a solvent, such as tetrahydrofuran for example. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time što je navedeni korak A5 u prisutnosti katalizatora, kao što je bimetalni katalizator kao što je platina/željezo na ugljenu na primjer, naročito 1% Pt/0.2% Fe/C, koji je navlažen vodom, po izboru otopljen u otapalu ili u suspenziji u otapalu, kao što je na primjer tetrahidrofuran.
wherein a compound of formula (4): is allowed to react with ethylenediamine, thereby providing a compound of formula (5). 
pri čemu je spoj s formulom (4): ostavljen da reagira s etilendiaminom, čime se dobiva spoj formule (5).
The method according to any one of claims 17 to 19, wherein said compound of formula (4): is prepared by the following step A3, wherein a compound of formula (3): is allowed to react with benzyl bromide, thereby providing a compound of formula (4). 
Postupak prema bilo kojem od zahtjeva 17 do 19, naznačen time što se navedeni spoj s formulom (4): priprema pomoću slijedećeg koraka A3, pri čemu je spoj s formulom (3): ostavljen da reagira s benzil bromidom, čime se dobiva spoj formule (4).
The method according to any one of claims 20 to 23, wherein said compound of formula (3): is prepared by the following step A2, wherein a compound of formula (2): is allowed to react with a base, thereby providing a compound of formula (3). 
Postupak prema bilo kojem od zahtjeva 20 do 23, naznačen time što se navedeni spoj s formulom (3): priprema pomoću slijedećeg koraka A2, pri čemu je spoj s formulom (2): ostavljen da reagira s bazom, čime se dobiva spoj formule (3).
The method according to any one of claims 24 to 26, wherein said compound of formula (2): is prepared by the following step A1, wherein a compound of formula (1): is allowed to react, in solution in a solvent, with nitric acid and sulphuric acid, thereby providing a compound of formula (2). 
Postupak prema bilo kojem od zahtjeva 24 do 26, naznačen time što se navedeni spoj s formulom (2): priprema pomoću slijedećeg koraka A1, pri čemu je spoj s formulom (1): ostavljen da reagira, u otopini u otapalu, s dušičnom kiselinom i sumpornom kiselinom, čime se dobiva spoj formule (2).
adding guanidine hydrochloride, followed by heating, then, 
dodavanje gvanidin hidroklorida, uz zagrijavanje, zatim,
adding water and an aqueous solution of a base, followed by heating, then, 
dodavanje vode i vodene otopine baze, uz zagrijavanje, zatim,
adding an amine, and filter, then 
dodavanje amina, i filtriranje, zatim
adding an aqueous solution of a mineral acid, thereby providing a compound of formula (9b): 
dodavanje vodene otopine mineralne kiseline, čime se dobiva spoj formule (9b):
The method according to any one of claims 29 to 35, wherein in said step A10, e), said mineral acid is hydrochloric acid. 
Postupak prema bilo kojem od zahtjeva 29 do 35, naznačen time što u navedenom koraku A10, e), navedena mineralna kiselina je klorovodična kiselina.
wherein copanlisib, of formula (10): is allowed to react with hydrogen chloride, thereby providing copanlisib dihydrochloride (11): 
pri čemu je kopanlisib, s formulom (10): ostavljen da reagira s hidrogen kloridom, čime se dobiva kopanlisib dihidroklorid (11):
The method according to claim 40, wherein said hydrogen chloride is hydrochloric acid. 
Postupak prema zahtjevu 40, naznačen time što je navedeni hidrogen klorid klorovodična kiselina.
The method according to any one of claims 1 to 41, wherein copanlisib (10) or copanlisib dihydrochloride (11) is prepared via the following steps shown in Reaction Scheme 3, infra: 
Postupak prema bilo kojem od zahtjeva 1 do 41, naznačen time što se kopanlisib (10) ili kopanlisib dihidroklorid (11) priprema pomoću slijedećih koraka prikazanih u Reakcijskoj shemi 3, ispod:
-R3A is independently linear or branched saturated C1-6alkyl; 
R3A je neovisno ravni ili razgranati zasićeni C1-6alkil;
A compound according to claim 1, wherein -L5XA-, if present, is -CH2-. 
Spoj prema zahtjevu 1, naznačen time, da -L5XA-, ako je prisutan, tada je -CH2-.
A compound according to claim 1 or 2, wherein -Q is pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, or diazepanyl, wherein the point of attachment is via a ring carbon atom, and is substituted with "n" groups -J, and is substituted with "m" groups -RQ. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da -Q je pirolidinil, piperidinil, morfolinil, piperazinil, azepanil, ili diazepanil, pri čemu je točka priključenja preko ugljikovog atoma u prstenu, i supstituiran je s "n" skupina –J, te je supstituiran s "m" skupina –RQ.
A composition comprising a compound according to any one of claims 1 to 18, and a pharmaceutically acceptable carrier or diluent. 
Sastav, naznačen time, da obuhvaća spoj u skladu s bilo kojim od zahtjeva 1 do 18, i farmaceutski prihvatljivi nosač ili razrjeđivač.
An in vitro method of inhibiting CDK function in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 18. 
Postupak in vitro inhibiranja djelovanja CDK u stanici, naznačen time, da obuhvaća stavljanje u doticaj stanice s učinkovitom količinom spoja u skladu s bilo kojim od zahtjeva 1 do 18.
A compound for use according to claim 22, in a method of treatment of a proliferative disorder. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da služi u postupku liječenja proliferativnog poremećaja.
A compound for use according to claim 22, in a method of treatment of cancer. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da služi u postupku liječenja raka.
A compound for use according to claim 22, in a method of treatment of a neurodegenerative disorder, including Alzheimer's disease and Parkinson's disease. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da služi u postupku liječenja neurodegenerativnog poremećaja, uključujući Alzheimerovu bolest i Parkinsonovu bolest.
A compound for use according to claim 22, in a method of treatment of a renal disease. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da služi u postupku liječenja ishemije.
A compound for use according to claim 22, in a method of treatment of a cardiovascular disorder, including atherosclerosis. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da služi u postupku liječenja kardiovaskularnog poremećaja, uključujući aterosklerozu.
A compound for use according to any one of claims 22 to 29, wherein the treatment further comprises treatment with a further active agent which is an aromatase inhibitor, an anti-estrogen, a Her2 blocker, or a further cytotoxic chemotherapeutic agent. 
Spoj za uporabu prema bilo kojem od zahtjeva 22 do 29, naznačen time, da navedeno liječenje nadalje obuhvaća liječenje s dodatnim djelatnim sredstvom koje je inhibitor aromataze, anti-estrogen, blokator za Her2, ili neko daljnje citotoksično kemoterapeutsko sredstvo.
A method of seamlessly connecting over-the-top, OTT, networks and Traditional Telecommunication Networks, TTN, comprising: 
Postupak za jednostavnog spajanja “over-the-top”, OTT, mreža i Tradicionalnih Telekomunikacijskih Mreža, TTN, koji obuhvaća:
receiving by a TTN Telecommunications Service Provider, TSP, from a calling party a dialed number of a called party; communicating by said TSP the dialed number in parallel to an OTT service provider and to a TTN service provider; 
TTN Davatelj Telekomunikacijskih Usluga, TSP, prima od pozvanog broja pozivatelja birani broj; navedeni TSP komunicira birani broj paralelno OTT davatelju usluga i TTN davatelju usluga; paralelnom provjerom:
by said OTT service provider whether it can terminate said call; 
da li OTT davatelj usluga može prekinuti navedeni poziv;
by said TTN service provider whether it can terminate said call; and communicating said checking results to the TSP; and terminating said call by one of said OTT and TTN service providers, wherein 
da li TTN davatelj usluga može prekinuti navedeni poziv; i komuniciranje navedenih rezultata provjere TSP-u; i jedan od navedenih OTT i TTN davatelja usluga usmjerava navedeni poziv, pri čemu provjera komunikacije obuhvaća barem jedno od:
the communication test comprises at least one of: sending a small number of packets, waiting for the called party's terminal to reply, testing the arrival times of the replies and estimating connectivity; and 
slanja malog broja paketa, čekanja kako bi terminal pozvanog odgovarao, testiranje vremena dolaska odgovora i procjene povezivanja; i posljednji puta provjeru terminala pozvane strane je bio pozivan ili je bio u interakciji i korištenje izmjerenih parametara kvalitete posljednje interakcije.
An isolated antibody, or an antigen-binding fragment thereof, that neutralizes infection of a group 1 subtype and a group 2 subtype of influenza A virus and comprises: (i) the heavy chain CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NOs: 1, 41 and 43, respectively, or as set forth in SEQ ID NOs: 1, 41 and 42, respectively; and (ii) the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 4, 5 and 6, respectively, or as set forth in SEQ ID NOs: 44, 5 and 6, respectively, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NOs: 59 or 55; and a light chain variable region having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NOs: 57 or 61 and wherein said antibody, or antigen-binding fragment thereof, is produced in transfected cells at titers of at least 3 fold higher than the titer at which FI6 variant 2 is produced. 
Izolirano protutijelo, ili njegov ulomak koji veže antigen, koje neutralizira infekciju podskupa grupe 1 i podskupa grupe 2 virusa influence A i obuhvaća: (i) sekvence CDR1, CDR2 i CDR3 teškog lanca kao što je navedeno u SEQ ID NOs: 1, 41 i 43, redom, ili kako je navedeno u SEQ ID NOs: 1, 41 i 42, redom; i (ii) sekvence CDR1, CDR2 i CDR3 lakog lanca kako je navedeno u SEQ ID NOs: 4, 5 i 6, redom, ili kako je navedeno u SEQ ID NOs: 44, 5 i 6, redom, pri čemu navedeno protutijelo ili njegov ulomak koji veže antigen sadrži varijabilnu regiju teškog lanca koja ima najmanje 90% identičnosti sekvence prema sekvenci aminokiseline kako je navedeno u SEQ ID NOs: 59 ili 55; i varijabilnu regiju lakog lanca koja ima najmanje 90% identičnosti sekvence prema sekvenci aminokiseline kako je navedeno u SEQ ID NOs: 57 ili 61 i pri čemu se navedeno protutijelo, ili njegov ulomak koji veže antigen, proizvodi u transfektiranim stanicama u titrima od najmanje 3 puta višim od titra u kojem se proizvodi FI6 varijanta 2.
an antibody or antigen binding fragment thereof in which the heavy chain of said antibody, or antigen-binding fragment thereof, contacts the amino acid at position 318 in HA1 and amino acid residues at positions 18, 19, 20, 21, 38, 41, 42, 45, 49, 53, and 57 in HA2 of said first or second monomer, and wherein said monomer is uncleaved or cleaved; 
protutijelo ili njegov ulomak koji veže antigen u kojem teški lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinom na položaju 318 u HA1 i aminokiselinskim ostatcima na položajima 18, 19, 20, 21, 38, 41, 42, 45, 49, 53, i 57 u HA2 navedenog prvog ili drugog monomera, i pri čemu se navedeni monomer ne cijepa ili cijepa;
an antibody, or antigen-binding fragment thereof in which the light chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues at positions 38, 39, and 43 in HA2 of said proximal monomer, and amino acid residues at positions 327, 328, and 329 in HA1 and 1, 2, 3, and 4 in HA2 of said distal right monomer, and wherein said proximal and said distal right monomers are uncleaved; 
protutijelo, ili njegov ulomak koji veže antigen u kojem laki lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima na položajima 38, 39, i 43 u HA2 navedenog proksimalnog monomera, i aminokiselinskim ostatcima na položajima 327, 328, i 329 u HA1 i 1, 2, 3, i 4 u HA2 navedenog distalnog desnog monomera, i pri čemu navedeni proksimalni i navedeni distalni desni monomeri se ne cijepaju;
an antibody, or antigen-binding fragment thereof in which the light chain of said antibody, or antigen-binding fragment thereof, contacts amino acid residues at positions 38, 39, 42, and 46 in HA2 of said proximal monomer and amino acid residues at positions 321 and 323 in HA1 and 7 and 11 in HA2 of said distal right monomer, and wherein said proximal and said distal right monomers are cleaved; 
protutijelo, ili njegov ulomak koji veže antigen u kojem laki lanac navedenog protutijela, ili njegov ulomak koji veže antigen, dolazi u kontakt s aminokiselinskim ostatcima na položajima 38, 39, 42, i 46 u HA2 navedenog proksimalnog monomera i aminokiselinskim ostatcima na položajima 321 i 323 u HA1 i 7 i 11 u HA2 navedenog distalnog desnog monomera, i pri čemu navedeni proksimalni i navedeni distalni desni monomeri se cijepaju;
an antibody, or antigen-binding fragment thereof that specifically binds to an epitope that comprises the amino acid at position 318 of HA1 and amino acid residues at positions 18, 19, 20, 21, 38, 39, 41, 42, 43, 45, 48, 49, 53, 56, and 57 of HA2 of said proximal monomer, and the amino acid residues at positions 327, 328, 329 of HA1 and amino acid residues at positions 1, 2, 3, and 4 of HA2 polypeptide of said distal right monomer, wherein said proximal and said distal right monomers are uncleaved; 
protutijelo, ili njegov ulomak koji veže antigen koje se specifično se veže za epitop koji sadrži aminokiselinu na položaju 318 od HA1 i aminokiselinskim ostatcima na položajima 18, 19, 20, 21, 38, 39, 41, 42, 43, 45, 48, 49, 53, 56, i 57 od HA2 navedenog proksimalnog monomera, i aminokiselinske ostatke na položajima 327, 328, 329 od HA1 i aminokiselinskim ostatcima na položajima 1, 2, 3, i 4 od HA2 polipeptida navedenog distalnog desnog monomera, pri čemu navedeni proksimalni i navedeni distalni desni monomeri se ne cijepaju;
an antibody, or antigen-binding fragment thereof that specifically binds to an epitope that comprises the amino acid at position 318 of HA1 and the amino acid residues at positions 18, 19, 20, 21, 38, 39, 41, 42, 45, 46, 49, 52, 53, and 57 of HA2 of said proximal monomer, and the amino acid residues at positions 321 and 323 of HA1 and amino acid residues at positions 7 and 11 of HA2 of said distal right monomer, wherein said proximal and said distal right monomers are cleaved; and 
protutijelo, ili njegov ulomak koji veže antigen koje se specifično se veže za epitop koji sadrži aminokiselinu na položaju 318 od HA1 i aminokiselinske ostatke na položajima 18, 19, 20, 21, 38, 39, 41, 42, 45, 46, 49, 52, 53, i 57 od HA2 navedenog proksimalnog monomera, i aminokiselinske ostatke na položajima 321 i 323 od HA1 i aminokiselinskim ostatcima na položajima 7 i 11 od HA2 navedenog distalnog desnog monomera, pri čemu navedeni proksimalni i navedeni distalni desni monomeri se cijepaju; i
A pharmaceutical composition comprising the antibody of any one of claims 1-7, or an antigen binding fragment thereof, the nucleic acid of claim 8 or 9, the vector of claim 10, or the cell of claim 11, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1-7, ili njegov ulomak koji veže antigen, nukleinsku kiselinu prema zahtjevu 8 ili 9, vektor prema zahtjevu 10, ili stanicu prema zahtjevu 11, te farmaceutski prihvatljivo sredstvo za razrjeđivanje ili nosač.
A B7-H1 blocking antibody for use in a method of treating cancer in combination with a radiation treatment, wherein the B7-H1 blocking antibody is administered following the radiation treatment, and wherein said B7-H1 blocking antibody is an anti-B7-H1 antibody. 
Antitijelo koje blokira B7-H1 za uporabu u postupku liječenja raka u kombinaciji s liječenjem radijacijom, pri čemu je antitijelo koje blokira B7-H1 primijenjeno nakon liječenja radijacijom, i pri čemu navedeno antitijelo koje blokira B7-H1 je anti-B7-H1 antitijelo.
The B7-H1 blocking antibody for the use according to claim 1, which is a monoclonal antibody to B7-H1. 
Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 1, koje je monoklonsko antitijelo za B7-H1.
The B7-H1 blocking antibody for the use according to claim 3, wherein the radiation treatment is a single or multiple X-ray irradiation. 
Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 3, pri čemu liječenje radijacijom je jednostruka ili višestruka iradijacija X-zrakama.
The B7-H1 blocking antibody for the use according to any one of claims 1-7, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer and melanoma. 
Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-7, pri čemu je rak odabran od skupine koja se sastoji od raka dojke, raka jajnika, raka mjehura, raka pluća, raka prostate, raka gušterače, raka debelog crijeva i melanoma.
The B7-H1 blocking antibody for the use according to claim 8, wherein the cancer is breast cancer or prostate cancer. 
Antitijelo koje blokira B7-H1 za uporabu prema zahtjevu 8, pri čemu rak je rak dojke ili rak prostate.
The B7-H1 blocking antibody for the use according to any one of claims 1-10, wherein said B7-H1 blocking antibody is administered within 9 days following the radiation treatment. 
Antitijelo koje blokira B7-H1 za uporabu prema bilo kojem od zahtjeva 1-10, pri čemu se navedeno antitijelo koje blokira B7-H1 primjenjuje unutar 9 dana nakon liječenja radijacijom.
is prepared by the following step A5: reacting a compound of formula (5): with hydrogen in the presence of a bimetallic catalyst, which is 1% Pt/0.2% Fe/C which is water-wetted in suspension in tetrahydrofuran, 
pri čemu spoj s formulom (5): ostavljen da reagira s vodikom u prisutnosti bimetalnog katalizatora, koji je 1% Pt/0.2% Fe/C koji je navlažen vodom u suspenziji u tetrahidrofuranu, čime se dobiva spoj formule (6).
a fusion protein comprising amino acid sequences of an immunoglobulin heavy chain and an iduronate-2-sulfatase, wherein the amino acid sequence of the iduronate-2-sulfatase is covalently linked to a carboxy terminus of the amino acid sequence of the immunoglobulin heavy chain; and 
fuzijski protein koji obuhvaća aminokiselinske sekvence jednog imunoglobulinskog teškog lanca i jedne iduronat-2-sulfataze (IDS), pri čemu je aminokiselinska sekvenca iduronat-2-sulfataze kovalentno vezana na karboksi-završetak od aminokiselinske sekvence imunoglobulinskog teškog lanca; i
The method of claim 1, wherein the fusion antibody is post-translationally modified by a sulfatase modifying factor type 1 (SUMF1). The method of claim 2, wherein the fusion antibody comprises formylglycine. 
Fuzijsko protutijelo prema zahtjevu 1 ili 2, naznačeno time, da je IDS modificiran posttranslacijski pomoću faktora modifikacije sulfataze tipa 1 (SUMF1), dok pritom IDS opcionalno obuhvaća formilglicin.
The intragastric balloon (10) as claimed in Claim 1, wherein there is no space between the expanded foam (62) and the sealed container. 
Intragastrički balon (10) sukladno patentom zahtjevu 1, pri čemu nema prostora između ekspandirane pjene (62) i zapečaćene posude.